Mitsubishi UFJ Trust & Banking Corp Decreases Position in DexCom, Inc. (DXCM)
Mitsubishi UFJ Trust & Banking Corp lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 398,533 shares of the medical device company’s stock after selling 8,537 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.46% of DexCom worth $29,153,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale increased its position in DexCom by 601.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 5,611 shares of the medical device company’s stock valued at $496,000 after buying an additional 4,811 shares during the period. Advisors Asset Management Inc. increased its position in DexCom by 4.1% in the first quarter. Advisors Asset Management Inc. now owns 8,179 shares of the medical device company’s stock valued at $693,000 after buying an additional 322 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its position in DexCom by 2.4% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 239,577 shares of the medical device company’s stock valued at $20,299,000 after buying an additional 5,641 shares during the period. Commerzbank Aktiengesellschaft FI bought a new position in DexCom during the first quarter valued at approximately $320,000. Finally, Great West Life Assurance Co. Can increased its position in DexCom by 6.4% in the first quarter. Great West Life Assurance Co. Can now owns 27,413 shares of the medical device company’s stock valued at $2,320,000 after buying an additional 1,647 shares during the period.
Shares of DexCom, Inc. (DXCM) opened at 74.96 on Friday. The stock’s market capitalization is $6.49 billion. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $96.38. The company has a 50-day moving average of $71.54 and a 200-day moving average of $74.57.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The business’s revenue was up 24.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.24) EPS. Equities research analysts anticipate that DexCom, Inc. will post ($0.77) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/mitsubishi-ufj-trust-banking-corp-decreases-position-in-dexcom-inc-dxcm/1537629.html.
Several analysts have recently issued reports on DXCM shares. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. B. Riley restated a “buy” rating and set a $95.00 target price on shares of DexCom in a research report on Sunday, May 7th. Canaccord Genuity restated a “buy” rating and set a $90.00 target price on shares of DexCom in a research report on Tuesday, August 22nd. ValuEngine upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research report on Friday. Finally, Jefferies Group LLC decreased their target price on shares of DexCom to $91.00 and set a “buy” rating on the stock in a research report on Tuesday, May 9th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. DexCom currently has an average rating of “Buy” and an average price target of $87.00.
In other news, EVP Richard Doubleday sold 1,635 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $75.26, for a total value of $123,050.10. Following the sale, the executive vice president now directly owns 72,395 shares of the company’s stock, valued at approximately $5,448,447.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Steven Robert Pacelli sold 1,450 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $78.19, for a total transaction of $113,375.50. The disclosure for this sale can be found here. Insiders sold a total of 32,179 shares of company stock worth $2,282,217 over the last three months. Insiders own 1.70% of the company’s stock.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.